JP2011006450A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011006450A5 JP2011006450A5 JP2010186933A JP2010186933A JP2011006450A5 JP 2011006450 A5 JP2011006450 A5 JP 2011006450A5 JP 2010186933 A JP2010186933 A JP 2010186933A JP 2010186933 A JP2010186933 A JP 2010186933A JP 2011006450 A5 JP2011006450 A5 JP 2011006450A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- cyclosporine
- composition
- surface stabilizer
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Claims (13)
- (a)2000nm未満の有効平均粒度を有する非晶質シクロスポリン粒子;及び
(b)前記非晶質シクロスポリン粒子の表面上に吸着された、少なくとも1つの非架橋型表面安定剤、
を含む、ナノ粒状シクロスポリン組成物であって、シクロスポリン及び少なくとも1つの表面安定剤が、10:1〜1.5:1(w/w)(シクロスポリン:表面安定剤)の比で存在する、組成物。 - 非晶質シクロスポリン粒子および結晶性シクロスポリン粒子の混合物であり、
該結晶性シクロスポリン粒子は2000nm未満の有効平均粒度を有し、少なくとも1つの非架橋型表面安定剤が該結晶性シクロスポリン粒子の表面上に吸着された、請求項1に記載の組成物。 - シクロスポリン粒子の有効平均粒度が、1500nm未満、1000nm未満、800nm未満、700nm未満、600nm未満、500nm未満、400nm未満約300nm未満、200nm未満、100nm未満、そして50nm未満から成る群から選択される、請求項1または2に記載の組成物。
- 固形の投与製剤である、請求項1〜3のいずれかに記載の組成物。
- 表面安定剤に対して、少なくとも2:1の比でシクロスポリンを有する、請求項4に記載の組成物。
- 液体分散製剤である、請求項1〜3のいずれかに記載の組成物。
- 液体分散の固形分が40%〜5%(w/w)である、請求項6に記載の液体分散。
- 注射製剤である、請求項6または7に記載の組成物。
- 前記表面安定剤が塩化セチルピリジニウム、ゼラチン、カゼイン、ホスファチド、デキストラン、グリセロール、アカシアゴム、コレステロール、トラガカント、ステアリン酸、塩化ベンズアルコニウム、ステアリン酸カルシウム、モノステアリン酸グリセロール、セトステアリルアルコール、セトマクロゴール乳化ワックス、ソルビタンエステル、ポリオキシエチレンアルキルエーテル、ポリオキシエチレンヒマシ油誘導体、ポリオキシエチレンソルビタン脂肪酸エステル、ポリエチレングリコール、ドデシルトリメチル臭化アンモニウム、ステアリン酸ポリオキシエチレン、コロイド性二酸化ケイ素、リン酸塩、ドデシル硫酸ナトリウム、カルボキシメチルセルロースカルシウム、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、カルボキシメチルセルロースナトリウム、メチルセルロース、ヒドロキシエチルセルロース、フタル酸ヒドロキシプロピルメチル−セルロース、非結晶性セルロース、アルミニウムケイ酸マグネシウム、トリエタノールアミン、ポリビニルアルコール、ポリビニルピロリドン、エチレンオキシド及びホルムアルデヒドを有する4−(1,1,3,3−テトラメチルブチル)−フェノールポリマー、ポロキサマー、ポロキサミン、ジミリストイルホスファチジルグリセロール、ジオクチルスルホコハク酸塩、スルホコハク酸ナトリウムのジアルキルエステル、ラウリル硫酸ナトリウム、スルホン酸アルキルアリールポリエーテル、ステアリン酸スクロースとジステアリン酸スクロースの混合物、p−イソノニルフェノキシポリ−(グリシドール)、構造−(−PEO)−−(−PBO−)−−(−PEO−)−のトリブロックコポリマー、エチレンオキシド及びプロピレンオキシドのブロックコポリマー、構造−(−PEO)−−(−PBO−)−−(−PEO−)を有し、そして約5000の分子量を有するトリブロックコポリマー、エチレンオキシド及びホルムアルデヒドを有する4−(1,1,3,3−テトラメチルブチル)−フェノールポリマー、ヒドロキシプロピルセルロース、並びにラウリル硫酸ナトリウム、から成る群から選択される、請求項1〜8のいずれかに記載の組成物。
- 請求項1〜9のいずれかに記載の組成物及び医薬として許容される賦形剤を含む、医薬組成物。
- (a)2000nm未満の有効平均粒度を有する非晶質シクロスポリン粒子;及び
(b)前記シクロスポリン粒子の表面上に吸着された、少なくとも1つの非架橋型表面安定剤を含むナノ粒状シクロスポリン組成物の製造方法であって、
前記シクロスポリン及び前記少なくとも1つの表面安定剤が、10:1〜1.5:1(w/w)(シクロスポリン:表面安定剤)の比で存在し、
前記方法は、2000nm未満の有効平均粒度を有し、そして10:1〜1.5:1(w/w)(シクロスポリン:表面安定剤)の薬物:表面安定剤の比を有するナノ粒状非晶質シクロスポリン組成物を提供するのに十分な時間及び条件のもとで、シクロスポリンを少なくとも1つの非架橋型安定剤と接触させることを含む、方法。 - 前記シクロスポリン粒子の有効平均粒度が1500nm未満、1000nm未満、800nm未満、700nm未満、600nm未満、500nm未満、400nm未満、300nm未満、200nm未満、100nm未満、そして50nm未満から成る群から選択される、請求項11に記載の方法。
- 前記組成物がミル粉砕によって得られる、請求項11または12に記載の方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/392,557 US6656504B1 (en) | 1999-09-09 | 1999-09-09 | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001521335A Division JP2003508492A (ja) | 1999-09-09 | 2000-09-07 | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011006450A JP2011006450A (ja) | 2011-01-13 |
JP2011006450A5 true JP2011006450A5 (ja) | 2012-01-05 |
Family
ID=23551058
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001521335A Pending JP2003508492A (ja) | 1999-09-09 | 2000-09-07 | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
JP2010186933A Pending JP2011006450A (ja) | 1999-09-09 | 2010-08-24 | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001521335A Pending JP2003508492A (ja) | 1999-09-09 | 2000-09-07 | 非晶質シクロスポリンを含んで成るナノ粒状組成物並びに当該組成物の製造方法及び使用方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6656504B1 (ja) |
EP (1) | EP1210104B1 (ja) |
JP (2) | JP2003508492A (ja) |
AT (1) | ATE322281T1 (ja) |
AU (1) | AU7119500A (ja) |
CA (1) | CA2384670C (ja) |
DE (1) | DE60027171T2 (ja) |
WO (1) | WO2001017546A1 (ja) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US7998507B2 (en) | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
CN1558755A (zh) | 2001-09-26 | 2004-12-29 | ���ع��ʹ�˾ | 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒 |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
DE10151392A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Cropscience Ag | Pulverförmige Feststoff-Formulierungen |
DE10154464B4 (de) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Oral verabreichbare pharmazeutische Zubereitung umfassend liposomal verkapseltes Taxol |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
CA2475092C (en) | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
ATE385777T1 (de) * | 2002-03-20 | 2008-03-15 | Elan Pharma Int Ltd | Nanopartikelzusammensetzungen von mitogen- aktivierten protein (map) kinase inhibitoren |
AU2003230691A1 (en) * | 2002-03-20 | 2003-10-08 | Elan Pharma International Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
EP1551457A1 (en) * | 2002-07-16 | 2005-07-13 | Elan Pharma International Limited | Liquid dosage compositions of stable nanoparticulate active agents |
DE10248619A1 (de) * | 2002-10-18 | 2004-04-29 | Bayer Ag | Verfahren zur Herstellung pulverförmiger Wirkstoff-Formulierungen mit kompressiblen Fluiden |
CA2513064C (en) * | 2003-01-31 | 2009-11-10 | Elan Pharma International, Ltd. | Nanoparticulate topiramate formulations |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20100297252A1 (en) * | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
ATE415946T1 (de) * | 2003-08-08 | 2008-12-15 | Elan Pharma Int Ltd | Neue metaxalon-zusammensetzungen |
ATE509618T1 (de) * | 2003-11-05 | 2011-06-15 | Elan Pharma Int Ltd | Nanoteilchenförmige zusammensetzungen mit einem peptid als oberflächenstabilisator |
US7910577B2 (en) * | 2004-11-16 | 2011-03-22 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
EP1835889A1 (en) * | 2004-12-15 | 2007-09-26 | Elan Pharma International Limited | Nanoparticulate tacrolimus formulations |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
KR20070118224A (ko) * | 2005-01-06 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 칸데사르탄 제제 |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
US20070065374A1 (en) * | 2005-03-16 | 2007-03-22 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
US8158153B2 (en) | 2005-03-17 | 2012-04-17 | Alkermes Pharma Ireland Limited | Nanoparticulate bisphosphonate compositions |
JP2008534509A (ja) * | 2005-03-23 | 2008-08-28 | エラン ファーマ インターナショナル リミテッド | ナノ粒子副腎皮質ステロイドおよび抗ヒスタミン薬の製剤 |
CA2604735A1 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International Limited | Nanoparticulate quinazoline derivative formulations |
WO2006110809A2 (en) * | 2005-04-12 | 2006-10-19 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
US7825087B2 (en) * | 2005-04-12 | 2010-11-02 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
WO2008073068A1 (en) | 2005-06-08 | 2008-06-19 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cefditoren |
US7297679B2 (en) * | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7276476B2 (en) | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US7501393B2 (en) * | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
CA2622758A1 (en) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
US7745400B2 (en) | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
US20080299210A1 (en) * | 2006-04-13 | 2008-12-04 | Min Wei | Stable nanosized amorphous drug |
WO2008002485A2 (en) * | 2006-06-23 | 2008-01-03 | Alza Corporation | Increased amorphous stability of poorly water soluble drugs by nanosizing |
TWI434926B (zh) * | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | 眼用組成物中聚氧化乙烯-聚氧化丁烯(peo-pbo)嵌段共聚物之使用 |
WO2008135828A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8703204B2 (en) | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
EP2162120B1 (en) | 2007-06-04 | 2016-05-04 | Bend Research, Inc | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
DE102007048705A1 (de) * | 2007-10-11 | 2009-04-16 | Bayer Healthcare Ag | Amorphe Formulierung |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
WO2009073215A1 (en) | 2007-12-06 | 2009-06-11 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
WO2009078755A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2009078754A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
WO2009078756A1 (en) | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
US20110182946A1 (en) * | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
HUE032426T2 (en) | 2009-05-27 | 2017-09-28 | Alkermes Pharma Ireland Ltd | Inhibition of flake aggregation in nanoparticulate meloxicam formulations |
AU2010261510A1 (en) | 2009-06-19 | 2012-02-09 | Nanoform Hungary Ltd. | Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
WO2010146606A1 (en) * | 2009-06-19 | 2010-12-23 | Sun Pharma Advanced Research Company Ltd., | Nanodispersion of a drug and process for its preparation |
TWI547522B (zh) * | 2009-07-07 | 2016-09-01 | 愛爾康研究有限公司 | 環氧乙烷環氧丁烷嵌段共聚物組成物 |
US8999312B2 (en) | 2010-06-02 | 2015-04-07 | Alcon Research, Ltd. | Use of PBO-PEO-PBO block copolymers in ophthalmic compositions |
AU2012262513B2 (en) * | 2011-05-27 | 2016-03-17 | Allergan, Inc. | A crystalline form of cyclosporine A, methods of preparation, and methods for use thereof |
HUP1300647A2 (hu) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik |
US10525012B2 (en) | 2015-08-11 | 2020-01-07 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
CN108553448A (zh) * | 2018-05-30 | 2018-09-21 | 江西师范大学 | 一种pH响应的药物缓释纤维素纳米颗粒的制备方法 |
WO2024085235A1 (ja) * | 2022-10-20 | 2024-04-25 | 中外製薬株式会社 | 環状ペプチドの結晶の製造方法 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3911099A (en) * | 1974-01-23 | 1975-10-07 | Defoney Brenman Mayes & Baron | Long-acting articles for oral delivery and process |
DE3013839A1 (de) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4663364A (en) | 1984-09-05 | 1987-05-05 | Kao Corporation | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
US4783484A (en) | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
JPS62185013A (ja) | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | 易吸収性医薬組成物 |
EP0262560A3 (en) | 1986-09-29 | 1989-07-05 | Ishihara Sangyo Kaisha, Ltd. | Benzoyl urea compound |
US4983605A (en) | 1986-10-23 | 1991-01-08 | Ishihara Sangyo Kaisha Ltd. | Pharmaceutical composition |
NL194638C (nl) * | 1986-12-19 | 2002-10-04 | Novartis Ag | Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. |
JP2661709B2 (ja) | 1988-07-08 | 1997-10-08 | ダウ・ケミカル日本株式会社 | 高活性な農薬水和剤の製法 |
JPH02196719A (ja) | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | 粉末状医薬組成物 |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
MX9201782A (es) * | 1991-04-19 | 1992-10-01 | Sandoz Ag | Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene. |
EP0593627A1 (en) | 1991-07-05 | 1994-04-27 | The University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
CA2231404C (en) | 1994-11-03 | 2009-02-17 | Arzneimittelwerk Dresden Gmbh | Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
IE75744B1 (en) | 1995-04-03 | 1997-09-24 | Elan Corp Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
WO1997007787A1 (en) * | 1995-08-25 | 1997-03-06 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
HU226608B1 (hu) * | 1996-08-22 | 2009-04-28 | Rtp Pharma Corp | Vízoldhatalan anyagok mikrorészecskéit tartalmazó készítmények és ezek elõállítására szolgáló eljárások |
IT1298575B1 (it) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | Composizioni farmaceutiche in forma di nanoparticelle comprendenti sostanze lipidiche e sostanze antifiliche e relativo processo di |
DK1079808T3 (da) * | 1998-05-29 | 2004-06-07 | Skyepharma Canada Inc | Præparater med termisk beskyttede mikropartikler og fremgangsmåde til slutdampsterilisering deraf |
DE19932157A1 (de) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln |
-
1999
- 1999-09-09 US US09/392,557 patent/US6656504B1/en not_active Expired - Fee Related
-
2000
- 2000-09-07 EP EP00959965A patent/EP1210104B1/en not_active Expired - Lifetime
- 2000-09-07 CA CA2384670A patent/CA2384670C/en not_active Expired - Fee Related
- 2000-09-07 AT AT00959965T patent/ATE322281T1/de not_active IP Right Cessation
- 2000-09-07 WO PCT/US2000/024505 patent/WO2001017546A1/en active IP Right Grant
- 2000-09-07 AU AU71195/00A patent/AU7119500A/en not_active Abandoned
- 2000-09-07 DE DE60027171T patent/DE60027171T2/de not_active Expired - Lifetime
- 2000-09-07 JP JP2001521335A patent/JP2003508492A/ja active Pending
-
2010
- 2010-08-24 JP JP2010186933A patent/JP2011006450A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011006450A5 (ja) | ||
JP2003508492A5 (ja) | ||
CA2384670A1 (en) | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions | |
EP3311845B1 (en) | Therapeutic polymeric nanoparticles and methods of making and using same | |
JP2016503030A5 (ja) | ||
JP2013535505A5 (ja) | ||
RU2017146716A (ru) | Способ образования наночастиц циклоспорина а/ циклодекстрина | |
JP2020531424A (ja) | メロキシカムを含有する注射用医薬組成物、およびその製造方法 | |
RU2014129268A (ru) | Офтальмологические составы, которые содержат привитые сополимеры поливинилкапролактам-поливинилацетат-полиэтиленгликоля | |
CA2472582A1 (en) | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer | |
AU2011294201B2 (en) | Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative | |
JP2020073564A5 (ja) | ||
RU2013113752A (ru) | Фармацевтическая композиция | |
JP2012523437A5 (ja) | ||
KR20210044245A (ko) | 주사가능 약학 조성물 및 이의 제조 방법 | |
JP2016507526A5 (ja) | ||
RU2012101817A (ru) | Композиции олмесартана медоксомила в форме наночастиц, способ их получения и содержащие их фармацевтические композиции | |
JP2008531721A5 (ja) | ||
WO2020247912A1 (en) | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof | |
JP2017516792A (ja) | 経口イソトレチノイン医薬組成物 | |
KR20200045415A (ko) | 아프레피탄트의 경구용 조성물 | |
ES2872552T3 (es) | Nanopartículas poliméricas y métodos de preparación y de uso de las mismas | |
JP2009517386A5 (ja) | ||
RU2015141792A (ru) | Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя | |
JP2017088629A (ja) | 二つの異なる粘性増強剤を有する粘性増強システムを備えた眼科用組成物 |